Introduction

What if a subtle inflammation, hidden deep within the eye, could quietly erode vision before symptoms become obvious? This is the challenge clinicians face with pars planitis, a rare and chronic form of intermediate uveitis that primarily affects the peripheral retina and vitreous base. Most commonly seen in children and young adults, pars planitis is characterised by idiopathic inflammation of the pars plana and adjacent structures. Its insidious progression often delays diagnosis, allowing complications such as cystoid macular oedema, vitreous opacities, and cataract formation to develop before intervention begins.

Among the therapeutic strategies available, corticosteroids remain the cornerstone of management. Their ability to suppress inflammation, modulate immune responses, and prevent structural damage to ocular tissues makes them the first-line approach in nearly all stages of the disease. However, the clinical decision regarding route of administration local, periocular, or systemic depends on disease severity, extent, patient-specific factors, and risk–benefit considerations.

This article provides an in-depth overview of corticosteroid therapy in pars planitis, examining the pharmacological rationale, administration routes, clinical indications, and safety considerations to guide optimal therapeutic decision-making.

What are corticosteroids?

Corticosteroids are synthetic analogues of hormones naturally produced by the adrenal cortex, primarily cortisol. They exert potent anti-inflammatory and immunosuppressive effects by inhibiting the production of pro-inflammatory cytokines, reducing vascular permeability, and modulating immune cell activity. In ophthalmology, corticosteroids are a cornerstone therapy for a range of intraocular inflammatory conditions, including pars planitis, because they can rapidly control inflammation, prevent tissue damage, and preserve visual function. Depending on the clinical scenario, they may be administered topically, periocularly, systemically, or via intraocular injection, each route offering distinct therapeutic advantages and safety considerations.¹

Pathophysiology of pars planitis

Pars planitis is classified as a subset of intermediate uveitis, with inflammation localised to the vitreous, peripheral retina, and pars plana. The hallmark clinical signs include snowbanking exudative deposits on the pars plana and snowballs, or aggregates of inflammatory cells within the vitreous cavity, a cavity that contains vitreous humour. Although its aetiology remains idiopathic, evidence suggests an autoimmune mechanism, with aberrant T-cell activation and cytokine release playing key roles in perpetuating inflammation.

Corticosteroids are highly effective in interrupting this pathological cascade. Their mechanisms of action include:

• Inhibition of pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α
• Suppression of leukocyte adhesion and migration into ocular tissues
• Stabilisation of vascular endothelial barriers, reducing oedema and exudation
• Downregulation of antigen presentation decreases auto-reactive immune activation

By targeting multiple points in the inflammatory pathway, corticosteroids rapidly reduce ocular inflammation, limit structural damage, and preserve visual acuity.²

Local corticosteroid administration: Targeted control of inflammation

Topical formulations: Limited utility in intermediate disease

Topical corticosteroids, such as prednisolone acetate 1%, are the first-line choice for anterior uveitis but are largely ineffective in pars planitis due to limited posterior segment penetration. Their use is primarily adjunctive, for example, when anterior chamber inflammation coexists with intermediate disease.

Clinical Considerations:

• Rapid onset of anterior segment involvement
• Minimal systemic absorption and lower systemic risk
• Ineffective as monotherapy for vitreous or retinal inflammation³

Intravitreal steroid delivery: Precision with sustained action

When localised inflammation persists despite systemic therapy or when targeted control is preferred, intravitreal corticosteroid delivery offers a highly effective solution. Injectable options such as dexamethasone implants or triamcinolone acetonide provide sustained intraocular drug levels and significant control of vitreous inflammation and macular oedema.

Advantages:

• Direct delivery to the site of pathology
• Sustained release over several months
• Rapid reduction of cystoid macular oedema

Limitations:

• Requires an invasive procedure with potential risks (endophthalmitis, vitreous haemorrhage)
• Risk of secondary glaucoma or cataract formation
• Typically reserved for refractory or recurrent cases⁴

Periocular corticosteroid Therapy: a balanced intermediate approach

Technique and pharmacokinetics

Periocular corticosteroid administration through posterior sub-Tenon’s, peribulbar, or orbital floor injections delivers high drug concentrations near the posterior segment without the systemic exposure associated with oral therapy. The most commonly used agent is triamcinolone acetonide (40 mg/mL), which diffuses into the vitreous and retina over several weeks.⁵

Clinical Indications:

• Moderate disease unresponsive to topical therapy
• Macular oedema secondary to inflammation
• Patients requiring local therapy without systemic exposure (e.g., children, those with systemic contraindications)

Therapeutic outcomes and monitoring

Periocular injections can achieve significant inflammation control and visual improvement, particularly in unilateral or asymmetric disease. They are often used as part of a stepwise approach before systemic therapy is considered.⁶

Advantages:

• Minimally invasive with localised delivery
• Effective for macular oedema and posterior segment inflammation
• Reduces systemic corticosteroid burden

Limitations:

• Temporary IOP elevation
• Potential for subconjunctival haemorrhage or globe perforation (rare)
• Repeated injections may be required

Systemic corticosteroid therapy: Comprehensive control for severe or bilateral disease

Indications and administration

Systemic corticosteroids are the mainstay for severe, bilateral, or vision-threatening pars planitis. They are also indicated when inflammation extends beyond the eye or when periocular therapy fails to achieve adequate disease control. Oral prednisone is the standard choice, typically initiated at 0.5–1 mg/kg/day, followed by a gradual taper over several weeks to months.⁷

Efficacy and clinical considerations

Systemic therapy achieves broad immunosuppression and rapid inflammation resolution. However, its use requires careful risk assessment due to potential adverse effects.

Advantages:

• Comprehensive control of bilateral and extensive inflammation
• Rapid resolution of active disease
• Flexibility for dose adjustments and tapering

Limitations:

• Risk of systemic side effects, including weight gain, hypertension, hyperglycemia, and osteoporosis
• Requires careful monitoring of metabolic and cardiovascular parameters
• Tapering is essential to prevent rebound inflammation

Pulse therapy for acute exacerbations

In acute, sight-threatening flares, intravenous methylprednisolone may be administered in high-dose pulses (e.g., 1 g/day for 3 days), followed by transition to oral therapy. This approach provides rapid immune suppression while minimising long-term systemic exposure.⁸

Safety considerations and monitoring protocols

Corticosteroids, while effective, carry risks that necessitate structured monitoring to prevent complications. The nature and frequency of monitoring depend on the route and duration of therapy.

Ocular safety monitoring

• Intraocular Pressure (IOP): Regular assessments to detect steroid-induced glaucoma
• Lens Examination: Early detection of posterior subcapsular cataracts
• OCT Imaging: Monitoring for macular edema resolution or recurrence⁹

Systemic safety monitoring

• Blood Pressure and Blood Glucose: Screening for metabolic disturbances
• Bone Density Assessments: Especially in long-term therapy
• Weight, Mood, and Electrolytes: Monitoring for corticosteroid-related metabolic and neuropsychiatric effects

Multidisciplinary care, involving ophthalmologists, rheumatologists, and primary care physicians, is often necessary for comprehensive management of systemic risks.

Emerging therapeutic perspectives and steroid-sparing strategies

While corticosteroids remain indispensable, their long-term toxicity drives the search for alternative or adjunctive therapies. Advances include:

• Immunomodulatory Agents (IMT): Drugs such as methotrexate, azathioprine, and mycophenolate mofetil are used as steroid-sparing agents in chronic disease
• Biologic Therapies: Monoclonal antibodies targeting TNF-α (e.g., adalimumab) have shown significant efficacy in refractory cases
• Novel Delivery Systems: Next-generation sustained-release implants aim to improve therapeutic precision and reduce complications¹⁰

These evolving strategies hold promise for reducing corticosteroid exposure while maintaining long-term disease control.

FAQs

What are corticosteroids?

Medicines that mimic natural hormones to reduce inflammation and calm the immune system.

How do they help in pars planitis?

They quickly control eye inflammation and protect vision.

What are the main ways they’re given?

As eye drops, injections near the eye, pills, or direct eye injections.

What is local corticosteroid therapy?

It delivers medicine directly to the inflamed area for targeted relief.

What is systemic therapy?

Medicine is taken by mouth or injection to treat inflammation throughout the body.

What is periocular therapy?

Injections are given around the eye to reduce inflammation without full-body effects.

Are corticosteroids safe?

Yes, but they must be used carefully under medical supervision.

What are common side effects?

They may raise eye pressure, cause cataracts, or suppress immunity.

How long does treatment last?

It depends on disease severity, but many patients need long-term or repeated therapy.

Summary

Pars planitis represents a complex clinical challenge, requiring early recognition and tailored management to prevent vision-threatening complications. Corticosteroids remain the cornerstone of therapy, offering rapid, potent, and reliable control of ocular inflammation. The choice of administration route, whether it is local, periocular, or systemic, must be guided by disease severity, anatomical involvement, patient comorbidities, and long-term safety considerations.

Local therapies provide targeted control with minimal systemic exposure, periocular injections offer a balanced intermediate solution, and systemic corticosteroids deliver comprehensive suppression for severe or bilateral disease. Emerging therapies and steroid-sparing agents continue to expand the therapeutic landscape, offering hope for improved outcomes with fewer adverse effects.

For clinicians, the challenge lies not just in selecting the right corticosteroid approach but also in orchestrating a long-term management strategy that prioritises both vision preservation and patient quality of life.